Avenue Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 7 - Stockholder's Equity (Details Textual)

Note 7 - Stockholder's Equity (Details Textual) $ / shares in Units, $ in Millions				6 Months Ended	29 Months Ended
	Jun. 24, 2024 shares	May 10, 2024 $ / shares	Feb. 03, 2023 USD ($)	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) $ / shares shares	Mar. 31, 2025 shares	Dec. 31, 2024 $ / shares shares	Apr. 28, 2024 USD ($) $ / shares shares	Jan. 05, 2024 USD ($) $ / shares shares	Nov. 30, 2023 $ / shares shares	Jan. 31, 2023 $ / shares shares	Jan. 30, 2023 shares	Sep. 22, 2022	Dec. 31, 2021 shares	Sep. 13, 2019 $ / shares	Sep. 13, 2016 shares
Preferred Stock, Shares Authorized (in shares)				2,000,000	2,000,000		2,000,000									2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.0001	$ 0.0001		$ 0.0001
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares		$ 0.0001		0.0001	0.0001		0.0001
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 8.64	$ 8.64		$ 8.64
Class of Warrant or Right, Outstanding (in shares)				1,476,200	1,476,200		1,476,200
Common Stock, Shares, Issued (in shares)				3,183,558	3,183,558		2,108,670
Invagen Pharmaceuticals Inc [Member]
Contingent Fee, Percentage of Proceeds of Future Financings			7.50%
Contingent Fee, Maximum Allowable Amount \| $			$ 4.0
Payment of Contingent Fee \| $				$ 0.2	$ 1.4
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $				$ 0.1	$ 0.1
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year
Deferred Restricted Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)				235,000	235,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $				$ 0.3	$ 0.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year
Two Thousand Fifteen Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,070,223													3,556
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				4,575,868	4,575,868
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Two Thousand Fifteen Incentive Plan [Member] \| Maximum [Member] \| Incentive Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	5,000,000
Two Thousand Fifteen Incentive Plan [Member] \| Maximum [Member] \| Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)												70,223
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	500,000
January 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											25,871
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares									$ 22.545		$ 116.25
November 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								221,333		194,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 22.545	$ 22.545	$ 22.545
New Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									220,538
Warrants and Rights Outstanding, Term (Year)									5 years
Warrants and Rights Issued Classified as Deemed Dividend \| $									$ 0.6
New Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									220,538
Warrants and Rights Issued Classified as Deemed Dividend \| $									$ 4.3
January 2024 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								441,076
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 22.545
Class of Warrant or Right, Outstanding (in shares)						0
October 2022 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								27,271
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 116.25
New Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								689,680
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 6.2
Warrants and Rights Issued Classified as Deemed Dividend \| $								$ 0.2
Common Stock, Shares, Issued (in shares)								0
New Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								689,680
Warrants and Rights Issued Classified as Deemed Dividend \| $								$ 4.5
May 2024 Warrant Inducement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 0.125
ATM Agreement [Member]
Commission Fee, Percent Fee		3.00%
Preferred Class A [Member]
Preferred Stock, Shares Authorized (in shares)																250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares															$ 0.0001
Preferred Stock, Convertible, Conversion Ratio													1,125